Surging Biovail merely catching up
Article Abstract:
Biovail Corporation International of Mississauga, Ontario, is an international full-service pharmacetical company involved in the formulation, clinical testing, registration and manufacture of drugs. The company posted 26% increase in its earnings in 2nd qtr 1999 as a result of increase market share of tiaza and a series of new product introductions, including a generic version of the cardiology drug Verelan in the US. The company is also awaiting approval of six generic dugs from the US Food and Drug Administration.
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Analysts see bright future for QLT
Article Abstract:
QLT PhotoTherapeutics Inc's reached a 52-week high of C$79.15 after its Visudyne therapy to prevent blindnesss was labeled a blockbuster drug. The company is also seeking the FDA approval to market its drug for age-related macular degeneration in the US. Stock analysts predict that sales of Visudyne will reach more than $500 million in the third year after its launch, with its stock reaching about C$100 with the approval of the FDA.
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 1999
User Contributions:
Comment about this article or add new information about this topic: